- Conditions
- Health
- Interventions
- Dinalbuphine sebacate, Nalbuphine HCl
- Drug
- Lead sponsor
- Lumosa Therapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cypress, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Maternal Anaesthesia and Analgesia Affecting Fetus or Newborn, Breast Feeding, Fentanyl, Bupivacaine, Nalbuphine
- Interventions
- Not listed
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Healthy Participants
- Interventions
- NAL ER, Quinidine Sulfate
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
- Interventions
- nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- NAL ER, Placebo
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pain, Sickle Cell Disease
- Interventions
- Morphine, Nubain
- Drug
- Lead sponsor
- Children's Healthcare of Atlanta
- Other
- Eligibility
- 6 Years to 19 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Uremic Pruritus, Pruritus
- Interventions
- nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID, Placebo tablets BID
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
- Conditions
- Healthy Participants
- Interventions
- NAL ER, Pirfenidone, Nintedanib
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prurigo Nodularis
- Interventions
- Nalbuphine ER Tablets, Placebo Tablets
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Fremont, California • Laguna Niguel, California + 32 more
- Conditions
- Hepatic Impairment
- Interventions
- Nalbuphine ER
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- NAL ER, Placebo
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 16
- States / cities
- Tuscaloosa, Alabama • New Britain, Connecticut • Wilmington, Delaware + 12 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- NAL ER, Placebo
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 32
- States / cities
- Newport Beach, California • Palm Springs, California • Redding, California + 29 more
- Conditions
- Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome
- Interventions
- nalbuphine plus naloxone, nalbuphine plus placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy
- Interventions
- nalbuphine plus naloxone, nalbuphine plus saline, naloxone plus saline
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy Participants
- Interventions
- NAL ER
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Uremic Pruritus, Pruritus
- Interventions
- nalbuphine HCl ER
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more